A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
Marc Gurwith,Deon Smith,Paul Bird,Jessica Leung,Mark Bloch,Joshua Kim,Rahul Mohan,Anthony Houston,Oscar Cumming,Ann Madrid,Ullrich Schwertschlag,Jerry Liu,Roy Wu,Jason Xu,Adam Jin,William Dongfang Shi
